Search

Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

About NRG Oncology

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

 

Click here to access all weekly broadcasts

 


NCORP Badge English636404806468909532



NRG Oncology is proud to be an 
active participant of Cancer Moonshot.

NCORP

Learn about the leaders and plans for NRG Oncology's NCORP Research Base.

 


NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
267-519-6630
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please email info@nrgoncology.org

What’s New

NRG Featured Research at SABCS 2019 Read more

NRG Oncology Trial Shows Immunotherapy is Safe Following Chemoradiotherapy for Women with Node-Positive Cervical Cancer Read more

NRG Oncology Trial Shows Neurocognitive Function Decline but Stable Quality of Life in First Year After Temozolomide-based Chemoradiotherapy for Patients with High Risk, Low-Grade Gliomas Read more

NRG Oncology Trial shows that Breast Cancer Recurrence after Lumpectomy and Radiation is Treatable with Localized Radiation without Mastectomy Read more

NRG Oncology Highlighted at SNO 2019 Including a Plenary Session Presentation Read more

NRG Oncology Trial Shows that Surgical Debulking of Ovarian Cancer at the Time of Recurrence Does not Extend Survival Read more

The NRG Oncology November 2019 eNewsletter is now available. Read more

We mourn the passing of Bernard Fisher, MD (August 23, 1918 – October 16, 2019). He was a Distinguished Service Professor of Surgery at University of Pittsburgh, and founding member and past chairman of the NSABP. His profound research changed & improved the standard of care for women with breast cancer. We extend our deepest sympathies to his family. Condolences to the family may be directed to the following address: The Fisher Family, 5636 Aylesboro, Pittsburgh, PA 15217. E-mail condolences may be sent to Dr. Beth Fisher at Bfisher917@gmail.com. Click here to view Dr. Fisher's legacy.com obituary which includes information where contributions can be made in his honor.

The NRG Oncology October 2019 eNewsletter is now available. Read more

NRG Oncology, in partnership with the RTOG Foundation, NSABP Foundation, and GOG Foundation, seek to support attendees to the NRG Oncology Semi-annual meeting occurring January 9-11, 2020 at the Marriott Marquis in Houston, Texas.  Meeting registration will be opening soon!  Applications for travel awards are due by the close of business October 25, 2019 (10/25/2019) and applicants will be notified by November 22, 2019 (11/22/2019) if they have been selected for an award.  The travel award application can be found here.

Call for research proposals: seeking a ctDNA assay partner as an integral biomarker in an upcoming colorectal cancer study. Please see RFA. Read more

A Letter from the NRG Oncology Group Chairs on Rare Tumor Trials Read more

Oncology Substudy Show Cosmetic Changes are Equivalent after Whole Breast Irradiation versus Partial Breast Irradiation for Women with Early Stage Breast Cancer Read more

Reduced-Dose Intensity-Modulated Radiotherapy with Cisplatin Meets Predetermined Benchmarks for Progression-Free Survival and Swallowing-Related Quality of Life for Oropharyngeal Cancer Read more

NRG Oncology Trial Shows no Difference in Pain Response between Stereotactic Body Radiotherapy and Conventional Radiotherapy for Patients with Spinal Metastases Read more

Pre-Salvage RT PSA is Predictive of Hormone Therapy Benefit with Salvage RT for Men with Recurrent Prostate Cancer on NRG Oncology Trial Read more

NRG Oncology has 4 plenary session talks at ASTRO 2019 Read more

NRG Oncology research at ASTRO 2019 Read more

The NRG post-meeting eNewsletter for July 2019 is now available Read more

NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee Read more

Don't miss these sessions at #NRG19 Read more

NRG Oncology Trial Reaffirms Carboplatin and Paclitaxel Chemotherapy Alone Should Remain Standard Treatment for Endometrial Cancer Read more

Copyright 2019 by NRG Oncology